摘要
目的：了解杭州地区医院口服调脂药的应用情况及变化趋势。方法：对杭州地区20家医院2004-2006年口服调脂药的销售金额和用药频度进行回顾性分析。结果：调脂药总销售金额逐年上升，与2004年相比，2006年增长了47．4％。销售金额和DDDs排序列前几位的主要是阿托伐他汀钙、辛伐他汀、非诺贝特。结论：3-羟基3-甲基戊二酰辅酶A还原酶抑制剂在杭州地区占主导地位。
OBJECTIVE： To investigate the current application situation and the trend of development of oral hypolipidemic drugs in Hangzhou area. METHODS： The consumption sum and the defined daily dose （DDDs） of the oral anti - hyperlipidemia drugs in 20 hospitals in Hangzhou area during 2004-2006 were analyzed retrospectively. RESULTS： The consumption sum of hypolipidemic drugs increased year by year, up 47.4% in 201）6 as comapred with that in 2004. Atorvastatin calcium, simvastatin and fenofibrate ranked ahead in both consumption sum and DDDs. CONCLUSION： HMG-CoA reductase inhibitors assumed a dominant role among all the hypolipidemic drugs used in Hangzhou area.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第26期2016-2018,共3页
China Pharmacy
关键词
口服调脂药
用药金额
用药频度
用药分析
Oral hypolipidemic drugs
Consumption sum
DDDs
Analysis of drug use
